SOURCE: MediJane Holdings Inc.

March 24, 2014 07:00 ET

MediJane Holdings Inc. Discusses Mission Statement and Growth Strategies Within Medicinal Marijuana Sector

LONGMONT, CO--(Marketwired - Mar 24, 2014) - MediJane Holdings Inc. (OTCQB: MJMD) ("MediJane" or "MJMD" or the "Company") is pleased to provide this discussion regarding its recent acquisition of the exclusive North American license to certain medicinal cannabis products and delivery systems developed by Colorado-based Phoenix Bio Pharmaceuticals Corporation ("Phoenix Bio Pharm"). In addition, this licensing agreement should allow MediJane to enhance Phoenix Bio Pharm's established relationships with physicians, scientists, product developers, biochemists, botanists, pharmacists, operators of growing facilities, dispensaries, and production facilities within the pharmaceutical and medical cannabis industries. 

Mr. Ronald Lusk, CEO of MediJane, commented, "While most companies within the booming marijuana sector are focused on crop optimization and capital intensive brick and mortar operations, MediJane's mission and focus is obtaining unique, innovative, and efficient delivery of medicinal marijuana to the target treatment area of the patient. Many industry experts predict that state legislation of medical cannabis will far outpace recreational legalization, and as such, MediJane's prime directive will remain focused on building a portfolio of pharmaceutical grade medical cannabis products and delivery systems."

MediJane's initial product launch will be the release of what we believe to be an innovative "Daytime Pain plus CBD" capsule. The pain and inflammation reducing pill targets chronic, neuropathic, arthritic, and back pain, without drowsiness. The four (4) hour dosage allows for accurate and controlled delivery of cannabinoids directly into the pain sufferer's system. This smokeless alternative is MediJane's initial launch into the chronic pain management market, which is estimated at over $45 billion annually in North America.

"We expect the Daytime Pain plus CBD capsule to be just the beginning for MediJane. In addition to a wide range of condition specific capsules and transdermal patches, many other medicinal marijuana products and delivery systems, including vaporizers, topical creams, and spray mists, are also being developed under the Phoenix Bio Pharm License Agreement. Our next phase of expansion should include gaining more mainstream credibility for it products within the medicinal marijuana community as more states legalize medical cannabis. It is one of our primary goals to ensure that all products will someday be available in traditional retail outlets like pharmacies and pain management clinics across the country and internationally," stated Mr. Lusk.

Mr. Lusk continued, "Over the coming days and weeks, MediJane plans to accelerate its growth strategy. Expanding our team of expert medical and marijuana project partners who can lead the charge in executing our business plan, providing insights and contacts to help enable MediJane to launch a national model for safe and legal access to cannabinoid based medicines." Lusk continued, "The next logical step is to begin a national state by state roll out. We will identify states based on distribution infrastructure, state policies, and market potential."

Spike Humer, CEO of Phoenix Bio Pharmaceuticals, concluded, "We have built an exceptional team of professionals that has allowed us to establish a host of significant relationships within the pharmaceutical and medicinal marijuana industries. We believe that these existing relationships will help to integrate and implement many of MediJane's growth strategies and resources as they release, roll out, and create distribution nationally in the ever increasing number of states where laws allow patients safe and legal access to medical marijuana products."

For more information, visit

Disclaimer/Safe Harbor: Some information in this MediJane Holdings Inc. (MJMD) press release constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause MJMD's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to MJMD herein are expressly qualified in their entirety by the above-mentioned cautionary statement. MJMD disclaims any obligation to update forward-looking statements contained in this press release, except as may be required by law.

Contact Information